Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A BIOEQUIVALENCE STUDY OF THE GENERIC BRINZOLAMIDE 1% OPHTHALMIC SUSPENSION COMPARED TO REFERENCE LISTED DRUG AZOPT® (BRINZOLAMIDE) OPHTHALMIC SUSPENSION 1% IN SUBJECTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

NCT03896633 is registered in ClinicalTrials.gov with Bausch & Lomb Incorporated as lead sponsor.

NCT NCT03896633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03896633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A BIOEQUIVALENCE STUDY OF THE GENERIC BRINZOLAMIDE 1% OPHTHALMIC SUSPENSION COMPARED TO REFERENCE LISTED DRUG AZOPT® (BRINZOLAMIDE) OPHTHALMIC SUSPENSION 1% IN SUBJECTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Lead sponsor
Bausch & Lomb Incorporated
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2018
Completion date
November 17, 2018
Enrollment
637 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glaucoma, open angle or ocular hypertension